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ABSTRACT 
Myeloproliferative neoplasm (MPN) patients suffer from fatigue and a reduced 
overall quality of life, both of which are not resolved with current pharmacologic therapy. 
The purpose of this study was to examine the effects of a 12-week online-streamed yoga 
intervention on fatigue and QoL in MPN patients as compared to a wait-list control group 
as well as to determine the feasibility of remotely collecting blood and saliva samples in a 
national sample. MPN patients were asked to complete 60 min/week of online yoga for 
12 weeks. MPN fatigue and QoL were assessed online with single-item questions taken 
from the MPN SAF (fatigue and QoL) and NIH PROMIS (QoL) at baseline, week 7, and 
week 12. The practicality of the blood and saliva measures were defined as >70% 
completion rate at both baseline and week 12. Fidelity of the intervention (i.e., weekly 
yoga participation) was assessed via both self-report (i.e., daily log) and objective 
measurement (i.e., Clicky). Of the 62 MPN patients that enrolled in the study, 48 
completed the intervention with 27 participating in the yoga group and 21 participating in 
the wait-list control group. Weekly yoga participation averaged ~41 min/week as 
measured objectively, whereas self-report yoga participation averaged ~56 min/week. 
The blood draw was determined to be practical with a 92.6% completion rate at baseline 
and a 70.4% completion rate at week 12. There were no significant differences from 
baseline to week 12 in MPN SAF fatigue (ES=0.18; p=0.724) or MPN SAF QoL (ES=-
0.53; p=0.19), however, NIH PROMIS QoL was significantly improved from baseline to 
week 12 (ES=0.7; p=0.031) when compared to the control group. This study builds upon 
the findings from a prior feasibility study in demonstrating the feasibility of online yoga 
as well as its preliminary effects of improving total symptom burden, fatigue, pain, 
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depression, anxiety, and sleep disturbance in MPN patients. Given the effects of yoga 
demonstrated both in the feasibility study and the current pilot study, a future randomized 
controlled trial with a larger sample size is warranted in order to further investigate the 
effectiveness of online yoga for MPN patient symptom burden and QoL. 
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INTRODUCTION 
In 2014, there were an estimated 1,665,540 new cancer cases and 585,720 cancer 
deaths in the United States.1,2 Hematological cancers, while less prevalent than some of 
the more common types of cancers (i.e., breast, prostate, lung & bronchus, colorectal), 
accounted for 9.4% of all cancers diagnosed as well as 3.3% of all cancer deaths in the 
United States in 2014.3 Hematological cancers represent a heterogeneous group of blood- 
and lymph-related disorders, including leukemia, Hodgkin lymphoma (HL), non-
Hodgkin lymphoma (NHL), myelodysplastic syndromes (MDS), myeloma, and 
myeloproliferative neoplasms (MPNs).3 
Compared to other hematological cancers, MPNs are relatively new, being first 
recognized in 1951 by William Dameshek as “myeloproliferative disorders.”4 The 
“classic” Philadelphia-negative myeloproliferative neoplasms, as they are now referred 
to, include polycythemia vera (PV), essential thrombocythemia (ET), and primary 
myelofibrosis (PMF). Each is characterized by mutually exclusive Janus Kinase 2 
(JAK2), calreticulin (CALR), and myeloproliferative leukemia oncogene virus (MPL) 
mutations. JAK2 mutation is the most frequently occurring gene mutation, occurring in 
approximately 98% of PV cases, 50-60% of ET cases, and 55-65% of PMF cases.5 Due to 
differences in the etiology between MPN sub-types, symptom profiles can vary greatly. 
Typical symptoms, however, include (but are not limited to) fatigue, pruritus, loss of 
appetite, night sweats, splenomegaly, abdominal pain, bone pain, weight loss, 
microvascular complications, and anemia.6,7  
Fatigue is the most commonly reported symptom among MPN patients. In a 
survey of 1179 MPN patients, fatigue was reported by 81% of patients.6 In separate 
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surveys, fatigue has been reported by as many as 92.7% of patients.8 Other commonly 
reported symptoms include insomnia (65.4%), sad mood (62.7%), early satiety (61.9%), 
concentration difficulties (61.7%), numbness (61.3%), inactivity (60.5%), sexual 
problems (57.9%), dizziness (55.2%), and pruritus (52.6%).8 
The symptom burden of MPNs often leads to a reduced overall quality of life 
(QoL), including a reduced ability to participate in physical and social functions as well 
as a reduced capacity to complete activities of daily living.6 As many as 84% of MPN 
patients report an impaired QoL, which has been defined as a score of >0 (0-10 scale) on 
the Myeloproliferative Neoplasm Symptom Assessment Form (MPN SAF).6  
Treatment for MPNs primarily focuses on managing disease progression as well 
as maintaining or improving QoL and reducing symptom burden. To date, pharmacologic 
approaches have been the mainstay of treatment options for the MPN patient population. 
Typical treatment options for this population may include, but are not limited to, 
pharmacotherapy (e.g., aspirin, hydroxyurea, interferon, cytoreduction, androgens, 
corticosteroids, erythropoiesis-stimulating agents, radioactive phosphorus (P3-32), and 
Janus Kinase (JAK) inhibitors), radiation therapy (e.g., splenic irradiation), surgery (e.g., 
splenectomy), or stem-cell transplantation.7,9 
Allogenic stem-cell transplantation is the only curative therapy for MPN patients, 
but is utilized very infrequently and is reserved for those afflicted with intermediate- to 
high-risk PMF. Given the lack of curative therapies for the treatment of MPNs, patients 
often live with a significant symptom burden for the rest of their life. Current 
pharmacologic approaches, specifically JAK-inhibitors, have demonstrated some success 
in improving symptom burden and overall QoL in MPN patients;7,10 however, these 
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treatment modalities often come with side effects (e.g., anemia, thrombocytopenia). For 
example, Ruxolitinib (selective JAK-inhibitor) has demonstrated efficacy in clinical trials 
for improving MPN-related symptoms (e.g., fatigue, inactivity, night sweats, 
muscle/bone pain, pruritus, early satiety, dyspnea, and abdominal discomfort) and QoL as 
well as reducing splenomegaly;11-16 however, anemia and thrombocytopenia are common 
side effects of this particular treatment.7,10 Additionally, MPN patients that do respond to 
treatment are often left with unresolved fatigue, depressive symptoms, and insomnia.17,18 
Thus, there is a need to explore other approaches (without side effects) to manage 
symptom burden and QoL in MPN patients.  
Yoga, which consists of physical postures (asanas) and mindfulness-based 
techniques (e.g., focus on breath, meditation, etc.) has been an effective approach to 
improve a variety of physical 
and psychosocial outcomes in 
other cancers (see Figure 1). 
Systematic reviews and meta-
analyses have found that 
yoga significantly improves 
functional well-being, 
distress, anxiety, depression, 
fatigue, emotional function, 
social function, sleep quality 
and QoL.19-21 Additionally, some studies have demonstrated a possible association 
between decreases in cortisol and improvements in psychosocial outcomes in cancer 
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patients.22,23 Vadiraja et al.23 demonstrated that mean diurnal cortisol levels decreased 
significantly (p<0.05; ES=0.27) along with significant improvements in anxiety 
(p<0.001), depression (p<0.01), and perceived stress (p<0.001) in breast cancer patients 
(n=88) participating in a 6-week, 3x/week yoga intervention. Much of the 
aforementioned work, however, has been done in breast cancer patients.  
Minimal research to date has examined the effects of yoga on MPN patient 
outcomes. There is non-experimental data indicating that MPN patients are interested in  
yoga as a symptom management strategy, particularly for fatigue. In a survey of 1788 
MPN patients, 73% reported attempting to exercise (43% of those attempted yoga) in 
order to self-manage fatigue, with 63% of these patients reporting exercise as a successful 
strategy.24 This data is cross-sectional, however, and requires further experimental 
investigation in order to identify physical activity, including yoga, as an effective 
symptom management (i.e., fatigue) for the MPN patient population. 
Our prior work lends support to the previous cross-sectional data.25 We conducted 
a 12-week feasibility of a home-based, online streamed yoga intervention in MPN 
patients (n=38). Online yoga was reported to be feasible as average yoga participation 
was ~50 min/week (60 min/week was prescribed) and 37% averaged ≥60 min/week of 
yoga. Furthermore, 68% were satisfied with the intervention and 75% felt that it was 
helpful for dealing with MPN-related symptoms. This study also provided preliminary 
evidence to support the role of yoga for improving MPN symptom burden and QoL 
outcomes as significant differences between pre- and post-intervention were seen in 
patient-reported total symptom burden (p=0.004; ES=-0.36), fatigue (p=0.04; ES=-0.33), 
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anxiety (p=0.002; ES=-0.67), depression (p=0.049; ES=-0.41), and sleep (p<0.0001; 
ES=-0.58).  
Although there are a few studies related to yoga and MPN patients, only one 
study provides experimental support for yoga. This study was conducted to determine the 
feasibility of online yoga as its primary outcome25 and did not include a control group 
and, therefore, the significant findings are preliminary in nature. Due to the limited 
research investigating the role of yoga in MPN patients as a non-pharmacological 
symptom management approach, a review of the literature as it relates  
to yoga in other hematological cancers will be discussed in the following section.  
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LITERATURE REVIEW 
Literature Review Methods 
The review was conducted by performing selective inclusion of studies 
investigating yoga (defined as the combination of physical postures and mindfulness 
techniques) in specific hematological cancer sub-types (see Table 1). Studies that  
 
examined yoga as an independent variable or a dependent variable were included as were 
intervention (e.g., RCT, quasi-experimental) or epidemiological (e.g., longitudinal, cross-
sectional) study designs. However, systematic reviews and meta-analyses as well as 
studies that examined yoga in relation to hematological cancer risk were excluded as this 
review intended to focus on primary research examining yoga and its effects on 
hematological cancer patient symptom burden and QoL. Additionally, studies including a 
patient population that underwent stem-cell transplantation were excluded, as this patient  
population may present with complications and issues that aren’t transferrable to the 
general MPN patient population. Stem-cell transplantation may result in acute and 
chronic complications, such as reduced immune function, prolonged neutropenia,  
Table 1. Inclusion/Exclusion Criteria 
Inclusion Criteria Exclusion Criteria 
- Published study between 1995-
2016 
- Examined any type of yoga as an 
either an independent variable or a 
dependent variable 
- Included leukemia, lymphoma, 
and/or myeloma patients or 
survivors as study participants 
- Intervention or epidemiological 
study design 
- Study participants included patient 
population receiving stem-cell 
transplantation  
- Examines yoga in relation to 
hematological cancer risk 
- Systematic review or meta-
analysis study design 
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infectious complications, veno-occlusive liver disease, and graft-vs-host disease,26 that 
aren’t typically present in the general MPN patient population as this type of surgery is 
usually reserved for high-risk PMF patients. A medical librarian developed search 
strategies for Ovid MEDLINE, Ovid Embase, and PubMed in order to identify articles. 
The search strategies were peer-reviewed by another experienced medical librarian. 
Limitations included a publication date range of 1995 to 2015. Search strategies included 
the MeSH terms and key words below (see table 2). A total of one article was included 
for review and is summarized in Table 3. 
Table 2. Keyword Search Terms 
MeSH Terms (PubMed) Keywords (PubMed) 
yoga yoga 
hematologic neoplasms multiple myeloma 
multiple myeloma leukemia 
leukemia lymphoma 
lymphoma  
Myeloproliferative disorders  
 
Literature Review 
Table 3. Summary of Included Articles 
Reference 
Study 
Design 
Study 
Sample 
Exercise 
Prescription 
Significant 
Findings 
Limitations 
Cohen et 
al., 2001 
RCT 
(wait-list 
control 
group) 
Lymphoma 
patients 
(n=39; 20 in 
intervention)  
7 weeks; 
1x/week; 
light-
intensity; 
unknown 
session 
duration; 
Tibetan yoga 
89% 
completed 2-3 
sessions; 57% 
completed ≥ 5 
sessions; 
↓sleep 
disturbance; 
↑sleep quality; 
faster sleep 
latency; ↓use 
of sleep meds 
Low overall 
exercise dose; 
small sample 
size in 
intervention 
group (n=20); 
yoga session 
duration not 
specified 
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The only article included in this review consists of a study conducted by Cohen et 
al.27 Lymphoma patients (n=39) were randomized to participate in a yoga intervention 
(n=20) or a wait-list control group (n=19). The intervention group performed Tibetan 
yoga (e.g., breathing, visualization, mindfulness, and low-impact postures) 1x/week for 
seven weeks (duration of each session was not specified). The primary outcomes for this 
study included sleep quality measures (i.e., overall quality, latency, duration, sleep 
medication use), state anxiety, depression, and fatigue. Although significant 
improvements in subjective sleep quality, faster sleep latency, longer sleep duration, and 
less reported use of sleep medications were found, there were no significant differences 
between groups for state anxiety, depression or fatigue. However, this may be due, in 
part, to both the adherence rate and the dose of the intervention. Only 58% of patients in 
the intervention group completed at least 5 yoga session (out of 7 total sessions). 
Additionally, seven total sessions may not have been a potent enough stimulus to 
improve psychosocial outcomes (i.e., anxiety, depression, and fatigue) as previous yoga 
studies demonstrating significant improvements in anxiety, depression, and fatigue in 
breast cancer patients have used higher doses (i.e., 18-24, 60-minute sessions).23,28,29 
Yoga interventions with doses greater than seven total sessions should be investigated in 
lymphoma patients. 
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STUDY PURPOSE & HYPOTHESES 
As demonstrated in the literature review, there is only one study providing 
preliminary support for yoga in hematological cancer patients. With much of the work 
being done in breast cancer patients, there is a strong need for future research examining 
the effects of yoga on MPN patient symptom burden and QoL. Eckert et al.30 has 
suggested in a recent review of the literature that, because of the success of physical 
activity interventions in other hematological cancer patients, the feasibility and 
effectiveness of physical activity interventions (including yoga) in MPN patients should 
be explored. Huberty et al.25 has successfully conducted a feasibility study investigating 
the effects of online-streamed yoga in MPN patients and has preliminary findings that 
demonstrate improvements in patient-reported fatigue and QoL-related outcomes.  
Therefore, the primary purpose of this study is to implement a pilot study further 
examining the effects of online-streamed yoga for fatigue and QoL in MPN patients as 
compared to a control group. Secondarily, the feasibility of collecting blood and salivary 
biomarkers that may be associated with fatigue will be investigated. 
Specific aim 1: To investigate the efficacy of online streaming yoga to reduce 
fatigue and improve QoL as compared to a wait-list control group in MPN patients. 
Hypothesis 1: Online streaming yoga will significantly improve patient-reported 
fatigue and QoL in MPN patients as compared to a wait-list control group. 
Specific aim 2: To explore the feasibility (i.e., implementation and practicality) of 
collecting blood (i.e., serum cytokines) and salivary (i.e., cortisol) biomarkers that may 
be associated with fatigue in MPN patients participating in an online yoga intervention. 
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Hypothesis 2: Blood (i.e., serum cytokines) and salivary (i.e., cortisol) biomarkers 
that may be associated with fatigue will be feasible (i.e., successfully implemented and 
practical) to collect in MPN patients participating in an online yoga intervention. 
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METHODS 
This study was approved by the Institutional Review Board at Arizona State 
University. All study participants completed an informed consent prior to participating. 
Study Participants  
Participants for the study included MPN patients with the following: 1) a 
diagnosis of essential thrombocythemia (ET), polycythemia vera (PV), or primary 
myelofibrosis (PMF) identified by a treating physician, 2) answered “no” to all items on 
the Physical Activity Readiness Questionnaire (PAR-Q) or be willing to obtain a signed 
medical release from their physician, 3) had access to a desktop or laptop on a regular 
basis, 4) had access to reliable internet, 5) been able to read and understand English, 6) 
were 18 years or older, 7) were willing to be randomized to a yoga group or a wait-list 
control group, and 8) were willing to drive to the nearest Patient Service Center to have 
their blood drawn. Potential participants were excluded if they: 1) currently performed 
Tai Chi, Qi Gong, or Yoga at least 60 minutes or more weekly, 2) currently participated 
in ≥150 minutes/week of physical activity, 3) currently utilized Udaya.com, 4) had a 
history of syncope in last 2 months, 5) had a history of recurrent falls (≥2 in 2 months), 6) 
had a score of ≥15 on the Patient Health Questionnaire (PHQ-9) indicating moderate-
severe clinical levels of depression, and 7) had an Eastern Cooperative Oncology Group 3 
(ECOG 3) score greater than three, 8) were currently pregnant, or 9) were currently 
residing outside of the United states of America. Table 4 describes the 
inclusion/exclusion criteria. 
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Table 4. Participant Inclusion/Exclusion Criteria 
Inclusion Criteria Exclusion Criteria 
- Diagnosis of ET, PV, or PMF 
- Answer “no” to all items on PAR-
Q or be willing to obtain medical 
release 
- Access to desktop or laptop on a 
regular basis 
- Access to reliable internet  
- Able to read and understand 
English 
- ≥18 years of age 
- Willing to be randomized to yoga 
group or wait-list control group 
- Willing to drive to the nearest 
Patient Service Center for blood 
draw 
- Currently perform Tai Chi, Qi 
Gong, or Yoga for ≥60 min/week 
- Currently engage in ≥150 
min/week of physical activity 
- Currently utilize Udaya.com  
- History of syncope in last 2 
months 
- History of recurrent falls (≥2 in 2 
months) 
- Score of ≥15 on PHQ-9 indicating 
moderate/sever levels of 
depression 
- ECOG 3 score >3 
- Currently pregnant 
- Currently residing outside of the 
United States of America 
 
Recruitment 
MPN patients were recruited nationally utilizing internet-based strategies, including 
social media (i.e., Facebook, Twitter), social networking sites, online and email listervs, 
and by contacting MPN patients that were not included in our prior feasibility study but 
expressed their interest in our future research. Prospective organizations were contacted 
via email and/or phone and asked to advertise the study by posting the provided 
recruitment material (i.e., flyers, blurbs) to their website or social media site. Those MPN 
patients that expressed interest in future studies were emailed and asked of their interest 
in the current study. Interested participants were then directed to an eligibility survey 
administered via Qualtrics (Provo, Utah).  
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Research Design 
The study was a randomized controlled trial study design. Sixty MPN patients 
were randomized, after consenting, to either a yoga group (n=~30) or a standard care, 
wait-list control group (n=~30). Participants randomized to the yoga group were asked to 
complete 12 weeks of at least 60 min/week of online-streamed, home-based yoga through 
Udaya.com (Udaya inc.). Those randomized to the wait-list control group were asked to 
resume their normal levels of physical activity for 16 weeks before being given access to 
the online yoga intervention materials (see Figure 2). The following sections describe the 
study-related procedures for the yoga group and the wait-list control group, respectively. 
Yoga Group 
The 12-week yoga prescription was a modified version of the yoga prescription 
from the previous feasibility study conducted by Huberty et al.31 The yoga prescription 
used in the feasibility study was designed to be safe and progressive for cancer patients 
and was approved by physicians on staff. Overall, the yoga prescription was 12-weeks 
and included 20-30 minute videos on 2-3x/week to achieve 60 minutes of yoga 
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participation each week. Weeks 1-2 were designed to be introductory in nature, with 
short class video lengths (i.e., 5-20 minutes). Class length and difficulty gradually 
progressed thereafter in weeks 3-12 to include longer and slightly more challenging 
videos (i.e., 20-30 minutes). Modifications to the yoga prescription used in the feasibility 
study included the addition of more meditation-based classes. These modifications were 
made based on qualitative feedback from the feasibility study, in which many participants 
mentioned that they wished there would have been more options for meditation classes. 
All study participants were provided with a yoga safety and modifications handout that 
they were asked to review prior to participating in yoga. Additionally, participants were 
reminded each week in a weekly email to participate in at least 60 minutes of yoga. 
Yoga group study participants were asked to receive a blood draw from a certified 
phlebotomist at a nearby Patient Service Center (PCS) at both baseline (week 0) and post-
intervention (week 12) in order to measure specific serum cytokines (i.e., IL-6 and TNF-
a) as well as complete blood count (CBC). They were also asked to provide saliva 
samples at both baseline (week 0) and post-intervention (week 12) to assess salivary 
cortisol. This measurement consisted of providing saliva samples at four different time 
points (i.e., upon waking, 30 min after waking, noon, and 30 min before bed) over the 
course of one day.  Yoga group participants were incentivized with $10 for completing 
their baseline blood draw and $20 for completing their post-intervention blood draw. 
Yoga group participants were also asked to complete weekly self-report logs (i.e., 
daily yoga logs) detailing the amount of time spent participating in yoga. Objective yoga 
participation was assessed using Clicky (i.e., web analytics program) and by gathering 
the amount of time (i.e., minutes) spent viewing yoga videos. Questionnaires were 
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administered at 4 time points throughout the study, including baseline (week 0), mid-
point (week 7), post-intervention (week 12), and follow-up (week 16). These 
questionnaires included questions pertaining to patient demographics, MPN-related 
health history information, study satisfaction, and both fatigue and QoL via the 
Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF). Yoga group 
participants were incentivized with $20 for completing all four questionnaires. 
Control Group 
Control group participants were not asked to receive blood draws or to provide 
saliva samples. Those in the control group were only asked to complete the 4 
questionnaires (baseline, mid-point, post- and follow-up). The questionnaires were 
identical to the questionnaires given to the yoga group, with the exception of any study 
satisfaction-related questions. Control group participants were also incentivized with $20 
for completing all four questionnaires. Upon completing the 4-week follow-up 
questionnaire, control group participants were provided with the same instructions that 
the yoga group received so that they could participate in 12-weeks of online yoga. There 
were no further measures for the control group to complete beyond week 16, however 
research staff was still available via email/phone if participants in the control group had 
questions related to the yoga prescription. 
Independent and Dependent Variables 
The independent variable in the proposed study was yoga. The dependent 
variables were fatigue, QoL, and feasibility of the blood draw. The yoga intervention was 
delivered over 12-weeks, was home-based, and streamed online. To answer the proposed 
hypotheses, fatigue was measured directly with a single question in the MPN SAF. QoL 
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outcomes included a single QoL question within the MPN SAF as well as a single 
question from the NIH PROMIS-10 Global Health measure. Self-reported raw scores 
were used for both the MPN SAF and NIH PROMIS-10 Global Health QoL measure. 
The feasibility of the blood draw and saliva sample collection was assessed through its 
practicality as described by Bowen et al.32 Practicality was defined as >70% of study 
participants completing both the pre- and post-intervention blood draw and saliva sample 
measures. 
Statistical Analyses 
Data collected from questionnaires and blood draws were entered into the 
Statistical Package for Social Sciences (SPSS) version 24.0 (Armonk, NY). Descriptive 
statistics (e.g., mean standard deviation, and frequencies) were calculated for both 
continuous and categorical variables with 95% confidence intervals. The Shapiro-Wilk 
test was used to check for normality with continuous variables because the expected 
sample size is <50. A p-value >0.05 signifies normally distributed data. All non-normal 
data was transformed to achieve normal distribution. Analysis of covariance (ANCOVA) 
was used to determine differences in outcome variables (i.e., fatigue, QoL measures) at 
week 7 and 12 between the yoga group and the control group, using the respective 
baseline score as a covariate. Cohen’s d was used to determine effect size values. Values 
of 0.2, 0.5, and 0.8 indicate small, moderate, and large effect size, respectively. A p-value 
of ≤ 0.05 was considered statistically significant.  
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RESULTS 
Participant Enrollment 
A total of 260 MPN patients completed the eligibility questionnaire, of which 
37% n=96) were eligible and the remaining 63% (n=164) were ineligible. Of those that 
were ineligible, the most common reasons were 1) currently physically active (49.3%; 
n=81), 2) score of ≥ 15 on PHQ-9 indicating moderate-severe depression (37.2%; n=61), 
and 3) currently engage in mindful activity of ≥ 60 min/week (26.2%; n=43) (see figure 
3). Those that were eligible for this study were emailed to schedule an intake 
appointment in the order in which they completed the eligibility questionnaire until ~60 
participants were enrolled in the study. Of the 96 that were eligible to participate, 62 were 
enrolled into the study with 34 randomized to the yoga group and 28 to the control group. 
A total of 48 participants completed all study-related procedures (i.e., completers), with 
27 yoga group participants and 21 control group participants completing the intervention. 
Of those that did not complete the intervention (i.e., dropouts; n=14), 50% (n=7) never 
responded after completing the informed consent, 28.6% (n=4) discontinued the 
intervention due to a personal issue not related to the study, and 21.4% (n=3) 
discontinued the intervention due to concerns with wearing the Fitbit device (i.e., too 
burdensome). Figure 3 describes study participant enrollment. 
Participant Demographics 
Table 5 describes participant demographics at baseline. Of the 48 participants that 
completed the intervention, mean (SD) age was 56.9±10.3 years and mean (SD) BMI was 
26.5±5.4 ml/kg2. The majority of participants were female (n=45), Caucasian (n=45), 
educated 
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Table 5. Baseline Demographics
Yoga Group 
(n=27) 
Control Group 
(n=21)
Total      
(n=48)
N (%) N (%) N (%) p
Age, years (M±SD) 58.3±9.3 55.0±11.4 56.9±10.3 0.28
BMI (M±SD) 26.6±5.4 26.2±5.6 26.5±5.4 0.81
Gender 0.71
     Male 2 (7.4) 1 (4.8) 3 (6.3)
     Female 25 (92.6) 20 (95.2) 45 (93.8)
Race 0.42
     Caucasian 25 (92.6) 20 (95.2) 45 (93.8)
     Other 2 (7.4) 1 (4.8) 3 (6.3)
Diagnosis 0.53
     Polycythemia Vera (PV) 10 (37.0) 5 (23.8) 15 (31.3)
     Essential Thrombocythemia (ET) 9 (33.3) 10 (47.6) 19 (39.6)
     Myelofibrosis (MF) 8 (29.6) 6 (28.6) 14 (29.2)
Time Since Diagnosis 0.44
     < 1 year ago 3 (11.1) 4 (19.0) 7 (14.6)
     1-3 years ago 4 (14.8) 4 (19.0) 8 (16.7)
     > 3 years ago 20 (74.1) 13 (61.9) 33 (68.8)
Presence of Enlarged Spleen 0.45
     Yes 8 (29.6) 9 (42.9) 17 (35.4)
     No 17 (63.0) 12 (57.1) 29 (60.4)
     Missing 2 (7.4) 0 (0.0) 2 (4.2)
History of Anemia 0.23
     Yes 15 (55.6) 8 (38.1) 23 (47.9)
     No 12 (44.4) 13 (61.9) 25 (52.1)
Ruxolitinib/Other JAK-Inhibitor Treatment 0.65
     Yes 5 (18.5) 5 (23.8) 10 (20.8)
     No 22 (81.5) 16 (76.2) 38 (79.2)
Education 0.3
     < High School 0 (0.0) 0 (0.0) 0 (0.0)
     High school diploma 2 (7.4) 0 (0.0) 2 (4.2)
     Some college 1 (3.7) 2 (9.5) 3 (6.3)
     Associates/2-year degree 3 (11.1) 0 (0.0 3 (6.3)
     Bachelors degree 10 (37.0) 8 (38.1) 18 (37.5)
     Graduate school or above 11 (40.7) 11 (52.4) 22 (45.8)
Marital status 0.28
     Single 2 (7.4) 0 (0.0) 2 (4.2)
     Partnered/in a relationship 1 (3.7) 2 (9.5) 3 (6.3)
     Married 22 (81.5) 19 (90.5) 41 (85.4)
     Separated 2 (7.4) 0 (0.0) 2 (4.2)
     Divorced 0 (0.0) 0 (0.0) 0 (0.0)
MPN SAF Fatigue*  (M±SD) 5.4±2.3 4.5±2.8 5.0±2.5 0.23
MPN SAF QoL**  (M±SD) 6.2±1.7 6.9±2.0 6.5±1.9 0.26
NIH PROMIS QoL***  (M±SD) 3.1±0.8 2.6±0.9 2.9±0.9 0.25
*Fatigue was a single question on the MPN-SAF with a possible score of 0-10;
a higher score represents greater fatigue
**MPN SAF QoL was a single question on the MPN-SAF with a possible score
of 1-10; a higher score represents greater QoL
***NIH Global Health QoL was a single question on the NIH Global Health 
Scale with a possible score of 1-5; a lower score represents greater QoL
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with Bachelor’s degree or higher (n=40), and married (n=41). ET was the most common 
diagnosis (n=19) followed by PV (n=15) and MF (n=14). The majority of participants 
were diagnosed with their MPN >3 years ago (n=33), did not have an enlarged spleen 
(n=29) and were not being treated with a JAK-Inhibitor (n=38). There were no significant 
differences in any demographic variables between groups (i.e., yoga vs. control). For all 
study participants, mean (SD) fatigue (MPN SAF) was reported as 5.0±2.5, mean (SD) 
QoL (MPN SAF) was reported as 6.5±1.9, and mean (SD) QoL (NIH Global Health) was 
reported as 2.9±0.9. 
Blood Draw and Salivary Cortisol Feasibility 
Practicality: At pre-intervention, 92.6% (n=25/27) of yoga group participants 
completed the blood draw and 93.3% (n=14/15 that were eligible) completed the salivary 
cortisol measure. At post-intervention, 70.4% (n=19/27) completed the blood draw and 
60% (n=9/15 that were eligible) completed the salivary cortisol measure. 
Yoga Participation 
Over the course of the 12-week yoga intervention, objective yoga participation 
(i.e., Clicky) averaged 40.8 min/week with approximately 15% (n=4/27) averaged ≥60 
min/week. There was a decrease in weekly yoga participation from week 1 (~92 
min/week) through week 7 (~30 min/week). Weekly yoga participation remained 
relatively stable around ~25-30 min/week from week 7 through week 12.  
Self-report yoga participation (i.e., daily yoga log) averaged 56.1 min/week with 
48% (n=13/27) averaging ≥60 min/week. There was an increase in weekly yoga 
participation from week 1 (~49 min/week) through week 3 (~77 min) before declining 
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back down to week 1 values in week 5 (~49 min/week). From week 5 through week 12, 
weekly yoga participation remained relatively stable between ~50-60 min/week.  
Yoga group participants significantly under-reported yoga participation in week 1 
(-45.5±55.9). In weeks 3-12, yoga group participants significantly over-reported yoga 
participation by 10.0±29.1 min/week at the lowest to 32.6±38.9 min/week at the highest. 
Figure 4 depicts the trends in weekly yoga participation and compares self-report vs. 
objective yoga participation. Table 6 describes the reliability of self-report vs. objective 
yoga participation and presents mean and median differences between self-report and 
objective yoga participation. 
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1Self-Report Yoga Min – Objective Yoga Min 
*T-Test (Mu0=0) 
 
Changes in Fatigue and QoL 
At mid-point (week 7), there were no significant differences in MPN SAF 
Fatigue, MPN SAF QoL, or NIH Global Health QoL between the yoga group and the 
control group. At post-intervention (week 12), there were no significant differences in 
MPN SAF Fatigue and MPN SAF QoL between the yoga group and the control group; 
however, there was a significant difference in NIH Global Health QoL between the yoga 
Table 6. Differences Between Self-Report and Objective Yoga Participation 
Week # 
Self-Report 
(Minutes) 
Objective 
(Minutes) 
Mean Diff 
(SD)1 
Median Diff1 P* 
1 49.2 92.4 -45.5 (55.9) -52.0 <0.001 
2 58.7 64.1 -12.0 (36.9) -6.5 0.11 
3 77.2 51.6 26.6 (41.6) 28.5 0.003 
4 58.4 39.7 19.5 (35.7) 7.2 0.01 
5 49.2 27.0 23.1 (25.3) 22.6 <0.001 
6 49.9 40.4 10.0 (29.1) 11.5 0.09 
7 61.7 30.3 32.6 (38.9) 26.7 <0.001 
8 51.3 29.4 22.7 (25.5) 21.1 <0.001 
9 47.4 29.9 18.1 (29.7) 6.4 0.005 
10 54.4 25.9 29.6 (30.0) 29.2 <0.001 
11 53.6 26.8 27.8 (28.8) 30.4 <0.001 
12 52.3 31.9 22.5 (29.7) 18.8 0.001 
Average 56.1 40.8 --- ---  
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group and the control group (ES=0.7; p=0.031). Table 7 describes the changes in fatigue 
and QoL across intervention time points. 
 
 
 
 
 
 
 
 
 
 
Table 7. Changes in Fatigue and QoL
Yoga Group 
(n=27)
Control Group 
(n=21)
Mean (SD) Mean (SD) d p
1
Fatigue
     Fatigue baseline* 5.4±2.3 4.5±2.8 - -
     Fatigue wk 7* 4.6±2.4 3.5±2.3 0.47 0.36
     Fatigue wk 12* 4.9±2.6 4.5±1.8 0.18 0.72
QoL
     MPN SAF QoL baseline** 6.2±1.7 6.9±2.0 - -
     MPN SAF QoL wk 7** 7.2±2.6 8.0±2.3 -0.33 0.4
     MPN SAF QoL wk 12** 6.4±2.4 7.4±1.2 -0.53 0.2
     NIH Global Health QoL baseline*** 3.1±0.8 2.6±0.9 - -
     NIH Global Health QoL wk 7*** 2.6±0.6 2.2±0.7 0.62 0.14
     NIH Global Health QoL wk 12*** 2.9±0.8 2.2±0.6 0.7 0.03
1
p-value obtained from ANCOVA using baseline score as covariate
Note: cohen's d was used for effect sizes
*Fatigue was a single question on the MPN-SAF with a possible score of 0-10; a higher score represents 
greater fatigue
**MPN SAF QoL was a single question on the MPN-SAF with a possible score of 1-10; a higher score 
represents greater QoL
***NIH Global Health QoL was a single question on the NIH Global Health Scale with a possible score 
of 1-5; a lower score represents greater QoL
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DISCUSSION 
The purpose of this study was to examine the efficacy of using online-streamed 
yoga to improve fatigue and QoL in MPN patients as compared to a wait-list control 
group. We also examined the feasibility of collecting blood samples and saliva samples 
from a national sample of MPN Patients. This study builds upon a previous feasibility 
study conducted by Huberty et al.25 in which 12-weeks of online-streamed yoga was both 
feasible and preliminarily effective at improving total symptom burden, fatigue, anxiety, 
depression, and sleep disturbance. The present study did not find any significant effects 
of yoga on fatigue when compared to a control group, however, QoL as measured by 
NIH PROMIS Global Health scale was significantly improved in the yoga group at the 
post-intervention time point (i.e., week 12) as compared to a control group. 
Over the span of six months (i.e., September 2016 to February 2017), we were 
able to recruit and enroll 62 study participants into the study. Additionally, within this 
same time period, 260 MPN patients completed the eligibility survey. It is not surprising 
that we were able to reach our recruitment goal of 60 MPN patients. In our prior 
feasibility study we were able to enroll 55 MPN patients in just two weeks.25 There is 
clearly an interest in complementary approaches among the MPN patient population with 
an impressive response rate in both our feasibility study as well as the current pilot study. 
Of the 260 MPN patients that completed the eligibility survey, 63% (n=164) were 
ineligible, with 1) currently physically active (n=81), 2) moderate-severe levels of 
depression (n=61), and 3) currently engage in regular mindful activity (n=43) being the 
most common reasons for ineligibility. This is similar to our prior feasibility study in 
which a diagnosis of depression, anxiety, or post-traumatic stress disorder as well as 
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currently engaging in regular mindful activity were the two most common reasons for 
ineligibility.25 
 Twenty three percent of participants dropped out of our study, which is 
comparable to other yoga interventions in cancer patients.33 In a recent systematic review 
of yoga interventions for fatigue in cancer patients and survivors, dropout rates ranged 
between 9% to 41%, with the average dropout rate being ~19% across 10 studies that 
were included in the review.33 However, the studies included in this review were in breast 
cancer patients (i.e., 9/10 studies in the review) and were of in-person yoga interventions 
as opposed to online, home-based yoga interventions. In health promotion interventions 
delivered online, dropout rates are ~32% on average according to a recent meta-
analysis.38 
We had fewer dropouts in the current study as compared to our prior feasibility 
study25 which had a dropout rate of 31%. Our prior feasibility study informed 
modifications to the current study which may have contributed to a smaller dropout rate. 
Participants in the original feasibility study reported wanting more meditative class 
options. Thus, we added short (i.e., 5-20 min) meditation videos as alternative videos for 
weeks 3-12.   
The blood draw was determined to be feasible based on a priori practicality 
criteria. More than 70% of study participants completed the blood draw measure at both 
pre-intervention (i.e., 92.6%) and post-intervention (i.e., 70.4%). The salivary cortisol 
measure was not determined to be feasible (i.e., not practical) as only 60% of study 
participants completed this measure at post-intervention, which was a 33% lower 
completion rate when compared to pre-intervention (i.e., 93.3%). Both the completion 
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rates for the blood draw and the salivary cortisol measure, however, are higher than what 
has been demonstrated in another study that aimed to determine the feasibility of 
collecting saliva, blood, or stool samples in an internet-based cohort of inflammatory 
bowel disease (IBD) patients.34 A total of 591 IBD patients were randomly invited to 
provide either 1) a blood sample through a mobile phlebotomy service, 2) a blood sample 
through a local physician’s office, or 3) a saliva sample via a mailed saliva collection kit. 
Of the 591 patients that were asked to provide a sample, only 28.9% (n=171) contributed 
a biospecimen, of which 90 were saliva samples, 47 were blood samples through mobile 
phlebotomy service, and 34 were blood samples through a physician’s office.34Although 
this study was not in cancer patients, it is the only study to the author’s knowledge that 
reported feasibility of collecting both blood and saliva samples in an internet-based study 
that included a national sample of study participants. Our completion rates for the blood 
and saliva measures between both pre- and post-intervention are higher than that 
demonstrated in this cross-sectional study. Despite the salivary cortisol measure being 
deemed impractical in our study and the completion rate decreasing from pre-intervention 
(i.e., 93.3%) to post-intervention (i.e., 60%), these completion rates are promising 
nonetheless. Especially because the salivary cortisol measure was not incentivized. 
Therefore it is possible that there was a greater drop-off in salivary cortisol completion 
rate from pre- to post-intervention when compared to the blood draw measure due to lack 
of incentive. Future studies should consider incentivizing completion of either/or the 
blood draw and saliva sample group as incentives may improve completion rates. 
For the entire 12-week intervention, objective yoga participation averaged ~41 
min/week while self-report yoga participation averaged ~56 min/week. Objective yoga 
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participation saw a steady decrease from week 1 (92.4 min) through week 5 (27.0 min), 
whereas self-report yoga participation increased steadily from week 1 (49.2 min) through 
week 3 (77.2 min) before decreasing slightly from week 4 (58.4 min) through week 6 
(49.9 min). Interestingly, there was a small spike in yoga participation at mid-
intervention for both objective and self-report yoga participation before remaining 
relatively stable at ~30 min/week for objective yoga participation and ~50 min/week for 
self-report yoga participation. 
It is difficult to know whether this level of discrepancy between self-report and 
objective yoga participation is typical as most of the literature has focused on the 
differences between self-report and objectively-measured physical activity (i.e., aerobic 
activity minutes). It has been demonstrated that self-reported physical activity is typically 
over-reported when compared to objectively-measured physical activity and that it is 
potentially due to a social desirability bias (i.e., desire to meet or exceed expectations) or 
the need for social approval (i.e., approval of a behavior).35,37 It is certainly possible that 
MPN patients in the present study over-reported their yoga participation in weeks 3-12 
due to a desire to appear more compliant with the prescribed 60 min/week of yoga or to 
gain approval from us as researchers for their efforts despite objectively participating in 
less than what they reported. 
Due to large, statistically significant differences between self-reported yoga 
participation and objectively-measured yoga participation across the 12-week 
intervention (all weeks except weeks 2 and 6), it seems that self-report may not be needed 
and/or necessary due to the potential for over-reporting. Therefore, future studies 
involving online yoga may be best served to assess study adherence and fidelity through 
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an objective measure of yoga participation due to the over-reporting of yoga participation 
that is apparent with self-report methods. Furthermore, eliminating self-report measures 
may also reduce participant burden as tracking yoga participation requires weekly or even 
daily time and energy on behalf of the participant. 
There was a significant improvement in NIH PROMIS QoL at post-intervention 
in the yoga group when compared to the control group. Although this was the only 
significant finding from the current study, it is important to note that there were non-
significant improvements in fatigue (ES=0.18; p=0.724) and MPN SAF QoL (ES=-0.53; 
p=0.19) from baseline to post-intervention for yoga group participants. Furthermore, 
moderate effect sizes of -0.53 and 0.7 for MPN SAF QoL and NIH PROMIS QoL, 
respectively, are promising considering the relatively small sample sizes in both the yoga 
group (n=27) and control group (n=21). These small sample sizes limited our ability to 
test effectiveness and could explain why we did not find significant improvements in 
fatigue and MPN SAF QoL. Additionally, the control group also improved across all 
three outcomes (i.e., MPN SAF fatigue, MPN SAF QoL, and NIH PROMIS QoL) from 
pre- to post-intervention, possibly explaining why there were non-significant 
improvements in fatigue and MPN SAF QoL in the yoga group. 
In our previous work, we identified online-streamed yoga as a potential 
complementary approach that could be recommended by physicians for MPN symptom 
management.25 Given the promising effects of yoga demonstrated in our feasibility study 
(i.e., improvements in total symptom burden, fatigue, depression, anxiety, pain, sleep) 
and the present pilot study (i.e., improvements in QoL), it seems that this suggestion still 
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holds merit. However, additional research is warranted to shed further light onto the 
effects that yoga has on MPN patient symptom burden and QoL.  
Our feasibility study demonstrated the potential for yoga to improve fatigue. 
Although there was a non-significant improvement in fatigue at mid-point and post-
intervention in the present study, it is important to note that the online yoga intervention 
did have a moderate effect on fatigue at mid-point (i.e., week 7) and a small effect at 
post-intervention (i.e., week 12). Fatigue is the most commonly reported symptom in 
MPN patients6 as well as one of the symptoms that is often left unaddressed by current 
pharmacologic treatment.17,18 Despite the non-significant improvements in the present 
study, the moderate effect seen at mid-point is promising and therefore, warrants a further 
exploration of the effects of yoga on fatigue in a randomized controlled trial with larger 
sample sizes. Additionally, these trials should explore the effectiveness of yoga on other 
commonly reported symptoms (e.g., pain, depression, anxiety, sleep disturbance, etc.) in 
order to determine which symptoms yoga may be most beneficial for. 
Limitations 
Although online yoga was effective for improving QoL and the blood draw 
measure was deemed to be feasible, there are a few limitations to note. First, small 
sample sizes in both the yoga group (n=27) and the control group (n=21) may have 
limited our ability to test effectiveness due to a lack of power. Future randomized control 
trials should include larger group sizes. Second, the majority of our sample was female 
(93.8%), potentially leading to a biased sample. The typical MPN patient population is 
~53% female,36 suggesting that we have a proportionately biased sample towards 
females. This may simply be due to the nature of our intervention (i.e., yoga) and the self-
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selecting process of enrollment that we had in place. Future studies should aim to include 
a more representative sample of males and females. This could be done by blinding 
potential study participants to the specific type of intervention (i.e., physical activity vs. 
yoga). Third, the BMI of our sample is 26.5±5.4 kg/m2, which is difficult to compare to 
published MPN patient norms as this data is not readily available. When comparing to the 
published norms for adults in the US (~26.5 kg/m2), however, our MPN patients’ BMI is 
very similar.39 National data on MPN patient characteristics is not currently available, 
despite this data existing for most other cancer types. A database containing MPN patient 
characteristics and demographics would be useful for future studies wanting to compare 
their patient population with population norms. Finally, the outcome measures included 
in this study were all single-question measures taken from validated questionnaires (i.e., 
MPN SAF and NIH PROMIS). It is possible that more robust questionnaires addressing 
multiple components of fatigue and QoL are needed to better detect changes in these 
outcomes. Although each of these single-item questions were taken from well-validated 
questionnaires, future studies examining changes in fatigue and QoL could consider 
including more comprehensive, multiple-item questionnaires to better assess these 
outcomes. For example, the Quality of Life Scale is a multidimensional QoL measure 
that has been validated in other chronic illness populations and the Brief Fatigue 
Inventory is a popular and validated multi-item fatigue scale used in cancer patients.  
Conclusions 
A 12-week, home-based, online yoga intervention is effective for improving QoL 
in MPN patients when compared to a wait-list control group and has a moderate, but not 
statistically significant, effect on fatigue. Additionally, collecting blood samples remotely 
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in a national sample is feasible (i.e., practical). This study builds upon a prior feasibility 
study that demonstrated online yoga’s feasibility and preliminary effects on MPN patient 
symptom burden. Collectively, these studies yield positive findings and warrant further 
research investigating the effects of online yoga for MPN patient symptom burden and 
QoL. Future randomized controlled trials should include larger sample sizes with a more 
representative gender distribution. Finally, given the feasibility of remotely collecting 
blood samples, an exploration of the effects of yoga on blood biomarkers associated with 
symptom burden in MPN patients is warranted.  
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APPROVAL: EXPEDITED REVIEW 
Jennifer Huberty 
SNHP: Exercise Science and Health Promotion 
Jennifer.Huberty@asu.edu 
Dear Jennifer Huberty: 
On 5/26/2016 the ASU IRB reviewed the following protocol: 
Type of Review: Initial Study  
Title: A Pilot Study of Online Yoga to Improve Symptom  
Burden (i.e., Fatigue) and Quality of Life in MPN 
Patients 
Investigator: Jennifer Huberty 
IRB ID: STUDY00004303 
Category of review: (2)(a) Blood samples from healthy, non-pregnant 
adults, (4) Noninvasive procedures, (7)(a) 
Behavioral research 
Funding: Name: Mayo Clinic Scottsdale 
Grant Title:  
Grant ID:  
Documents Reviewed • MPN Yoga_Email for previously interested 
MPN patients_4-27-16_RE.pdf, Category: 
Recruitment  
Materials; 
• Control Group Welcome Letter, Category: 
Participant materials (specific directions for them); • 
Control Group Important Dates , Category:  
Participant materials (specific directions for them); 
• Yoga Group Weekly Email Reminders, 
Category: Recruitment materials/advertisements 
/verbal scripts/phone scripts; 
• MPN Yoga_ Informed Consent_Modified_ 
5-24- 
16_RE.pdf, Category: Consent Form; 
• Yoga Group 4-Week Follow-Up 
Questionnaire, Category: Measures (Survey 
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questions/Interview questions /interview 
guides/focus group questions); 
• Pilot study IRB Draft_Modified_5-24-16 
RE.docx,  
Category: IRB Protocol; 
• Interview Questions, Category: Measures 
(Survey questions/Interview questions /interview 
guides/focus group questions); 
• MPNYoga_Flyer_NoTrackChanges_5-24-
16_RE.pdf, Category: Recruitment Materials; 
• Control Group Weekly Log, Category: 
Measures (Survey questions/Interview questions 
/interview guides/focus group questions); 
• Yoga Group Post-Intervention 
Questionnaire, Category: Measures (Survey 
questions/Interview questions /interview 
guides/focus group questions); • Yoga Group 
important Dates, Category: Participant materials 
(specific directions for them); 
• MPN Yoga_Professional Recruitment 
Blurb_Drs.  
Huberty&Mesa Bio_NoTrackChanges_5-24-16_RE  
(1).pdf, Category: Recruitment Materials; 
• Study Protocol, Category: Other (to reflect 
anything not captured above); 
• Mid-Point Questionnaire, Category: 
Measures (Survey questions/Interview questions 
/interview guides/focus group questions); 
• Yoga Group Daily Log, Category: Measures 
(Survey questions/Interview questions /interview 
guides/focus group questions); 
• Yoga Group Weekly log, Category: 
Measures (Survey questions/Interview questions 
/interview guides/focus group questions); 
• Yoga Group Welcome Letter, Category: 
Participant materials (specific directions for them); 
• Control Group 4-Week Follow-Up 
Questionnaire, Category: Measures (Survey 
questions/Interview questions /interview 
guides/focus group questions); 
• MPN Yoga_Social Media & Email  
Blurbs_NoTrackChanges_5-24-16_RE.pdf, 
Category:  
Recruitment Materials; 
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• Yoga Modifications Handout, Category: 
Participant materials (specific directions for them); 
• Eligibility Questionnaire, Category: 
Screening forms; 
• Yoga Prop Alternatives, Category: 
Participant materials (specific directions for them); 
• Control Group Post-Intervention 
Questionnaire, Category: Measures (Survey 
questions/Interview questions /interview 
guides/focus group questions); 
• Informed Consent for Eligibility 
Questionnaire_5- 
17-16_RE.pdf, Category: Consent Form; 
• Participant Fitbit Instructions, Category: 
Participant materials (specific directions for them); 
• Yoga Group Udaya Instructions, Category:  
Participant materials (specific directions for them); • 
Baseline Questionnaire, Category: Measures (Survey 
questions/Interview questions /interview 
guides/focus group questions); 
 
The IRB approved the protocol from 5/26/2016 to 5/25/2017 inclusive. Three weeks 
before 5/25/2017 you are to submit a completed Continuing Review application and 
required attachments to request continuing approval or closure.  
If continuing review approval is not granted before the expiration date of 5/25/2017 
approval of this protocol expires on that date. When consent is appropriate, you must use 
final, watermarked versions available under the “Documents” tab in ERA-IRB. 
In conducting this protocol you are required to follow the requirements listed in the  
INVESTIGATOR MANUAL (HRP-103). 
Sincerely, 
IRB Administrator 
cc: Ryan Eckert 
Ryan Eckert 
Rachael Nowak 
Lauren Martinez 
Jennifer Huberty 
Lindsay Hand 
Maritza Reyes 
Linda Larkey 
Jennifer Matthews 
